摘要
目的探讨异时性重复癌的远期疗效。方法对1975年—2011年住院治疗91例患者的临床资料和随访结果进行统计分析。结果首次患病部位：食管癌12例,宫颈癌39例,胃癌13例,乳腺癌10例,其他癌17例。二次患病部位：食管癌36例,宫颈癌7例,胃癌20例,乳腺癌4例,其他癌24例。2次发病间隔时间8个月~30年,平均8.16年。手术治疗：食管癌16例,宫颈癌28例,胃癌23例,乳腺癌14例,其他癌28例。放射治疗：食管癌28例,宫颈癌17例,其他癌3例。化疗：食管癌3例,胃癌8例,其他癌9例。总的1,3,5,10年生存率分别为100%（91/91）、94.32%（83/88）、81.71%（67/82）、67.18%（43/64）。首次患病和二次患病5年生存率比较：食管癌差异有统计学意义（P〈0.01）,宫颈癌差异无统计学意义（P〉0.05）,胃癌差异有统计学意义（P〈0.01）。结论第2次肿瘤复发和转移或未控制是异时性重复癌患者的主要死亡原因,治疗时应根据个体情况选择最优治疗方案。
Objective Discuss heterochrony repeat cancer treatment forward curative effect. Methods For the 1975-2011 hospitalized the clinical data of 91 patients and follow-up results were statistically analyzed. Results Ill place for the first time： 12 cases esophageal cancer, cervical cancer, 39 cases, 13 cases of gastric cancer, 10 cases of breast cancer, 17 cases of other carcinoma. 2 times sick place： esophageal 36 cases, cervical cancer 7 cases, 20 cases of gastric cancer, breast cancer, 4 cases, 24 cases of other carcinoma. 2 times incidence between 8 months to 30 years, an average of 1 year 11 months. 28 cases surgical treatment： 16 cases of esophageal cancer, cervical cancer, 23 cases of gastric cancer, breast cancer （14 cases, 28 cases of other carcinoma. 28 cases radiotherapy： esophageal cancer and cervical cancer, 17 cases of other carcinoma （3 cases）. Chemotherapy： esophageal cancer （3 cases）, 8 cases of gastric cancer, 9 cases of other carcinoma. The total 1, 3, 5, 10 year survival rates were 100% （91/91）, 94.32% （83/88）, 81.71% （67/82）, 67.18% （43/64）.Ⅲ and sick 2 times the 5-year survival rate for the first time comparison： esophageal cancer was statistically significant （P〈0.01）, cervical cancer has no statistical significance （P〉0.05）, and gastric cancer was statistically significant （P〈0.01）.Conclusion A second tumor recurrence and metastasis or without control is a major cause of death. Should choose according to individual condition, the optimal treatment plan.
出处
《基层医学论坛》
2013年第20期2597-2598,共2页
The Medical Forum
关键词
异时性重复癌
肿瘤复发
远期疗效
预后分析
Heterochrony repeat carcinoma Tumor recurrence The long-term outcome Prognostic analysis
